{"entity":{"id":"nct06478693","kind":"trial","name":"A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC","aka":[],"tldr":"A phase 1 trial of MT-303 run by Myeloid Therapeutics, now recruiting.","summary":"A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC is a phase 1 interventional study registered as NCT06478693 by Myeloid Therapeutics, with 70 participants planned, started 2024-07-01, primary completion expected 2027-12-31. Conditions recorded: Hepatocellular Carcinoma. Interventions recorded: MT-303, MT-303 +Atezolizumab + Bevacizumab.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT06478693","url":"https://clinicaltrials.gov/study/NCT06478693"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["mt-303"],"companies":["create-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06478693","phase":"1","setting":"A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including Hepatocellular Carcinoma","sponsor":"Myeloid Therapeutics","enrolled":70,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06478693/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"mt-303","kind":"drug","name":"MT-303","route":"/drugs/mt-303/"}],"company":[{"id":"create-medicines","kind":"company","name":"CREATE Medicines","route":"/companies/create-medicines/"}]}}